← Back to The Absolute Effect
Germ Cell Tumours · Medical · Stage I non-seminoma

SWENOTECA clinical stage I NSGCT management programme

In clinical stage I non-seminomatous germ-cell tumour, how does risk-adapted one-cycle BEP alter relapse risk compared with surveillance?

Population745 patients with clinical stage I NSGCT managed prospectively in Sweden and Norway.Risk factorVascular tumour invasion was used to guide treatment recommendations.InterventionOne cycle BEP in patients recommended adjuvant treatment; vascular-invasion-negative patients could choose surveillance or BEP.Key endpointRelapse, with disease-specific survival as the ultimate safety endpoint.

Absolute Effect

Vascular-invasion positive
41.7% surveillance vs 3.2% after 1-cycle BEP

Absolute relapse reduction ≈38.5 percentage points.

Vascular-invasion negative
13.2% surveillance vs 1.3% after 1-cycle BEP

Absolute relapse reduction ≈11.9 percentage points.

Clinical interpretation

Risk-adapted treatment sharply reduces relapse after orchiectomy, particularly in patients with vascular invasion, while surveillance remains an option for selected lower-risk patients.

No patient died from progressive disease in the reported cohort. The clinical trade-off is avoiding chemotherapy in patients who may never relapse versus accepting relapse risk and intensive salvage treatment.

Limitations

This was a prospective management programme rather than a single randomized comparison of BEP versus surveillance across all risk groups. Treatment choice was risk-adapted, so absolute differences should not be interpreted as randomized causal effects.

NNT

Because this is not a randomized two-arm trial, a formal NNT is not appropriate. The absolute relapse differences are reported directly to preserve the study design.

Primary / authoritative source

SWENOTECA management programme — PubMed

Current-practice context · reviewed 14 October 2026

SWENOTECA illustrates risk-adapted stage I NSGCT management using vascular invasion and structured follow-up to guide surveillance versus one-cycle BEP. Because this is a prospective non-randomized programme, outcomes by risk group should not be interpreted as causal comparisons; follow-up reliability, fertility, late effects and patient preference remain central.

Current guideline guidance ↗